top of page
Donate
About Us
Subscribe
Join the NTG
Contact Us
Home
Family Support
Professionals
NTG-EDSD
Training
NTG Training
Webinars
NTG USA Workshops
NTG Canada Workshops
Upcoming Events
Conference Events
Affiliated Regional Trainers
Canadian Consortium News
Presentations
Resources
Publications
News
Autism/ASD & Dementia
Behavioral Health Issues
Cerebral Palsy & Dementia
COVID-19 & ID
Dementia Care Management
Dementia Guidelines
Dementia Symptoms
Down Syndrome & Dementia
Down Syndrome 'Regression'
Facts about Dementia
Fragile X and Dementia
Frontotemporal Dementia
Lewy Body Dementia
Menopause, ID, & Dementia
Neuroatypical Screening
Pharmaceuticals
Severe/Profound ID
Projects
NTG News Blog
All Posts
Pharmaceutical
Down Syndrome
NTG-EDSD
COVID-19
Education
Clinical
International
NTG Activities
Family Support
Autism
Developmental Disabilities
Policy and Advocacy
Diagnostics
Search
NTG and LuMind IDSC Issue Advisory on Prescribing Criteria for Alzheimer's Therapeutics
Jun 1, 2023
1 min read
FDA Approves use of Leqembi for Alzheimer's
Jan 7, 2023
1 min read
Closure on Biogen's Aduhelm Launch - Congressional Report
Jan 3, 2023
1 min read
ENACT Act Will Help with Inclusion in Clinical Trials
Dec 20, 2022
1 min read
Biogen announces positive results for Alzheimer's drug Lecanemab
Dec 6, 2022
1 min read
Disappointing Results from Amyloid Reducing Drug Trial
Jun 21, 2022
1 min read
NTG Video on Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer's Disease
Oct 9, 2021
1 min read
Back to Top
bottom of page
